Trial Profile

A Multicenter, Non-randomized, Open-label, Multiple-Dose Phase I Study of NWY001, in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NWY 001 (Primary)
Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Ductal carcinoma; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Chipscreen Biosciences

Most Recent Events

05 Jan 2024 According to a NewWay Biosciences media release, first patient has been dosed at the Sun Yat-Sen University Cancer Center in China, the trial-leading institution.
05 Jan 2024 Status changed from not yet recruiting to recruiting, NewWay Biosciences media release.
14 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com